Progenics Pharmaceuticals Inc (PGNX)

Add to Watchlists
Create an Alert
4.33 -0.27  -5.87% NASDAQ Mar 22, 20:00 Delayed 2m USD
View Full Chart
PGNX Price Chart
View All Events

PGNX Events

Date Type Description
05/09/2019 08:30 EDT Misc Progenics Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Progenics Pharmaceuticals Inc First Quarter Earnings in 2019 Release
03/15/2019 Misc Progenics Pharmaceuticals Inc Annual Report in 2018
03/14/2019 08:30 EDT Misc Progenics Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018
03/14/2019 Earnings Progenics Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release
11/08/2018 08:30 EST Misc Progenics Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018
11/08/2018 Earnings Progenics Pharmaceuticals Inc Third Quarter Earnings Results in 2018
07/31/2018 Earnings Progenics Pharmaceuticals Inc Second Quarter Earnings in 2018 Release
06/13/2018 Misc Progenics Pharmaceuticals Inc Annual General Meeting in 2017
05/09/2018 08:30 EDT Misc Progenics Pharmaceuticals Inc First Quarter Earnings Conference Call in 2018
View All Performance Charts

PGNX Total Returns Comparison

Advertisement

PGNX One Page Reports

Edit

Profile

  • URL: http://www.progenics.com
  • Investor Relations URL: http://ir.progenics.com/
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 09, 2019
  • Last Earnings Release: Mar. 14, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

PGNX Comparables

Edit

PGNX Excel Add-In Codes

  • Name: =YCI("PGNX","name")
  • Description: =YCI("PGNX","description")
  • Sector: =YCI("PGNX","sector")
  • Industry: =YCI("PGNX","industry")
  • Est. Current Fiscal Year End: =YCI("PGNX","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.